Đang chuẩn bị liên kết để tải về tài liệu:
Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Everolimus (RAD001) is an orally administered mTOR inhibitor that is well known for its antitumor efficacy and that has been approved for the treatment of several solid tumors, including renal cell carcinoma. In gastric cancer (GC), despite previous preclinical and phase I/II studies suggesting the promising efficacy of everolimus in previously treated AGC, more recent trials revealed that only certain subsets of patients might benefit from treatment with everolimus. |

TÀI LIỆU LIÊN QUAN

Doctoral thesis in Business Administration: Key factors of the successful implementation of Statistical Process Control (SPC) in Vietnamese manufacturing enterprises

The occurrence of bovine babesiosis in a crossbred dairy cow and its successful therapeutic management

Using the interest rate tool to control inflation in Vietnam

Air and Water Pollution: Burden and Strategies for Control

Báo cáo y học: " Management of HIV-1 associated hepatitis in patients with acquired immunodeficiency syndrome: role of a successful control of viral replication"

Severe diaphragmatic dysfunction with preserved activity of accessory respiratory muscles in a critically ill child: A case report of failure of neurally adjusted ventilatory assist (NAVA) and successful support with pressure support ventilation (PSV)

SLC6A4 STin2 VNTR genetic polymorphism is associated with tobacco use disorder, but not with successful smoking cessation or smoking characteristics: A case control study

Ebook Key project management based on effective project thinking: Part 1

Successful control of a neonatal outbreak caused mainly by ST20 multidrug-resistant SHV-5-producing Klebsiella pneumoniae, Greece

Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression